Trinity Biotech (Trinity Biotech) Long-Term Debt

: $54.28 Mil (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

Trinity Biotech's Long-Term Debt for the quarter that ended in Sep. 2023 was $54.28 Mil.

Trinity Biotech's quarterly Long-Term Debt declined from Mar. 2023 ($63.14 Mil) to Jun. 2023 ($53.93 Mil) but then increased from Jun. 2023 ($53.93 Mil) to Sep. 2023 ($54.28 Mil).

Trinity Biotech's annual Long-Term Debt declined from Dec. 2020 ($82.70 Mil) to Dec. 2021 ($0.00 Mil) but then increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($58.05 Mil).

Trinity Biotech Long-Term Debt Historical Data

The historical data trend for Trinity Biotech's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Long-Term Debt

Get a 7-Day Free Trial

81.38

82.02

82.70

58.05

Trinity Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Long-Term Debt	Get a 7-Day Free Trial															57.70	58.05	63.14	53.93	54.28

Trinity Biotech (NAS:TRIB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Trinity Biotech Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (Trinity Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

TRBA:Germany

Address

IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website

https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.